Weight-loss drugs, particularly GLP-1 medications like Mounjaro and Wegovy, have rapidly become top sellers in India by value, despite limited patient numbers. This success is attributed to out-of-pocket spending, indicating a shift in consumer willingness to invest in long-term metabolic treatments for conditions like obesity. However, clinical questions persist regarding long-term efficacy, potential weight regain after cessation, and the completeness of patient access, with Indian data still scarce.